NASDAQ:QNCX Quince Therapeutics (QNCX) Stock Price, News & Analysis $26.81 -1.29 (-4.59%) Closing price 10/6/2026 04:00 PM EasternExtended Trading$24.52 -2.29 (-8.53%) As of 07:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Quince Therapeutics Stock (NASDAQ:QNCX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Quince Therapeutics alerts:Sign Up Key Stats Today's Range$26.81▼$28.1550-Day Range$22.00▼$34.5752-Week Range$15.10▼$909.98Volume27,750 shsAverage Volume22,433 shsMarket Capitalization$27.27 millionP/E RatioN/ADividend YieldN/APrice Target$206.71Consensus RatingModerate Buy Company Overview Quince Therapeutics, Inc. (NASDAQ:QNCX) is a clinical-stage biotechnology company developing therapies for rare and debilitating diseases. The company focuses on precision medicines designed to address underlying disease mechanisms and unmet medical needs in patient populations that may have limited treatment options. Quince’s pipeline includes efzofitimod, an investigational immunomodulator being developed for pulmonary sarcoidosis, a rare inflammatory disease that can affect lung function. The company is also advancing an erythrocyte-based drug-delivery platform, known as EryDex, which is designed to use a patient’s red blood cells to deliver therapeutic compounds. Its lead EryDex-based program is being evaluated for ataxia-telangiectasia, a rare inherited neurodegenerative disorder. The company was formerly known as Cortexyme, Inc. and adopted the Quince Therapeutics name as it shifted its strategic focus toward rare-disease therapeutics. Its research and clinical programs are intended for patients in the United States and international markets, subject to regulatory approval. Quince is headquartered in California and conducts development activities through collaborations and clinical studies in multiple regions.AI Generated. May Contain Errors. Read More Quince Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreQNCX MarketRank™: Quince Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 162nd out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingQuince Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on 2 strong buy ratings, 6 buy ratings, 3 hold ratings, and 2 sell ratings.Upside PotentialQuince Therapeutics has a consensus price target of $206.71, representing about 671.0% upside from its current price of $26.81.Amount of Analyst CoverageQuince Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Quince Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Quince Therapeutics are expected to grow in the coming year, from ($8.39) to ($3.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quince Therapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quince Therapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Quince Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.24% of the float of Quince Therapeutics has been sold short.Short Interest Ratio / Days to CoverQuince Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quince Therapeutics has recently decreased by 11.78%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQuince Therapeutics does not currently pay a dividend.Dividend GrowthQuince Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.50 News SentimentQuince Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Quince Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for QNCX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Quince Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Quince Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.60% of the stock of Quince Therapeutics is held by insiders.Percentage Held by Institutions30.75% of the stock of Quince Therapeutics is held by institutions.Read more about Quince Therapeutics' insider trading history. Receive QNCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quince Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QNCX Stock News HeadlinesQuince Shareholders Approve New Equity and Stock PlansOctober 6 at 5:31 PM | tipranks.comZacks Research Upgrades Quince Therapeutics (NASDAQ:QNCX) to HoldOctober 3, 2026 | americanbankingnews.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 7 at 1:00 AM | Profits Run (Ad)Quince Therapeutics Maps LAM-001 Trials, With BOS Data Due in 2027October 2, 2026 | americanbankingnews.comLeerink Partners Reaffirms Their Buy Rating on Quince Therapeutics (QNCX)October 1, 2026 | theglobeandmail.comQuince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome TranscriptSeptember 28, 2026 | seekingalpha.comQuince Therapeutics (NASDAQ:QNCX) Research Coverage Started at Rodman & RenshawSeptember 27, 2026 | americanbankingnews.comRodman & Renshaw initiates coverage of Quince Therapeutics with a buySeptember 24, 2026 | msn.comSee More Headlines QNCX Stock Analysis - Frequently Asked Questions How have QNCX shares performed this year? Quince Therapeutics' stock was trading at $670.00 on January 1st, 2026. Since then, QNCX stock has decreased by 96.0% and is now trading at $26.81. How were Quince Therapeutics' earnings last quarter? Quince Therapeutics, Inc. (NASDAQ:QNCX) announced its quarterly earnings data on Friday, August, 14th. The company reported ($12.31) earnings per share for the quarter, beating the consensus estimate of ($28.02) by $15.71. When did Quince Therapeutics' stock split? Shares of Quince Therapeutics reverse split on the morning of Tuesday, June 30th 2026.The 1-20 reverse split was announced on Friday, June 26th 2026. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 29th 2026. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Quince Therapeutics IPO? Quince Therapeutics (QNCX) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 4,412,000 shares at $16.00-$18.00 per share. How do I buy shares of Quince Therapeutics? Shares of QNCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Quince Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quince Therapeutics investors own include PayPal (PYPL), SoFi Technologies (SOFI), TherapeuticsMD (TXMD), Achilles Therapeutics (ACHL), Agile Therapeutics (AGRX) and Aytu BioPharma (AYTU). Company Calendar Last Earnings8/14/2026Today10/07/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 QNCX's financial health is in the Green zone, according to TradeSmith. QNCX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:QNCX Previous SymbolNASDAQ:CRTX CIK1662774 Webwww.quincetx.com Phone(415) 910-5717FaxN/AEmployees38Year FoundedN/APrice Target and Rating Average Price Target for Quince Therapeutics$206.71 High Price Target$1,000.00 Low Price Target$68.00 Potential Upside/Downside+671.0%Consensus RatingModerate Buy Rating Score (0-4)2.62 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($156.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$83.98 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-133.84% Debt Debt-to-Equity RatioN/A Current Ratio14.52 Quick Ratio14.52 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($128.18) per share Price / Book-0.21Miscellaneous Outstanding Shares1,017,000Free Float960,000Market Cap$27.27 million OptionableOptionable Beta1.33 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:QNCX) was last updated on 10/7/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
